Nexavar (sorafenib)
- Region
- 🇪🇺 EU
- Active substance
- sorafenib
- Company
- Bayer AG
- Status
- Authorised
- Therapeutic area
- Carcinoma, Hepatocellular; Carcinoma, Renal Cell
- EU approval
- Wed 19 Jul 2006
- Application
- EMEA/H/C/000690
- ATC
- L01EX02
- Official record
- www.ema.europa.eu
Indication
Hepatocellular carcinoma Nexavar is indicated for the treatment of hepatocellular carcinoma. Renal cell carcinoma Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. Differentiated thyroid carcinoma Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Sorafenib Accord Authorised · Accord Healthcare S.L.U.
Follow Nexavar
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.